Xintela

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

First quarter 2022
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 11,042 (loss: 9,047).
» Loss per share* was SEK 0.12 (loss: 0.12).
» At March 31, 2022, the equity/assets ratio** was -36 % (16).

* Earnings/loss per share: Profit/loss for the period divided by 89,134,021 shares, which was the number of registered shares at March 31, 2022. In the year-earlier period, the Company had 77,168,209 registered shares.
** Equity/assets ratio: Equity divided by total capital.

Significant events in the first quarter of 2022
» Bulletin from the extraordinary general meeting in Xintela. (January 17, 2022)
» Xintela granted 4.8 million SEK from Vinnova. (January 18, 2022)
» Xintela AB announced that the company received a loan of SEK 3 million. (March 21, 2022)

Significant events after the end of the period
» Xintela starts clinical study of XSTEM® in knee osteoarthritis. (April 4, 2022)
» Targinta selects ADC-antibody TARG9 as drug candidate. (April 5, 2022)
» Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting. (April 8, 2022)
» Xintela proposes Hans-Joachim Simons as new Board member. (May 3, 2022)
» Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model. (May 9, 2022)
» Xintela is conducting a capital raise that includes a fully guaranteed rights issue of approximately SEK 44.6 million and a supplementary directed issue of up to SEK 10 million on the same terms as the rights issue. (May 20, 2022)

The complete interim report is available for download below and on the company’s website www.xintela.se/en/investors#reports